Sign in
Taking people in SwitzerlandPhase 3

Xeomin injections compared with placebo for focal hand dystonia

Tests Xeomin injections against placebo in adults with focal hand dystonia.

Key facts

Who runs it
Alain Kaelin
Where
Bern, Lausanne, Lugano, Sankt Gallen, and Zurich, SwitzerlandSee the 5 sites
Trial code
Registry title
IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia
Status
Recruiting
Phase
Phase 3
People taking part
48 people, planned
Started
21 Feb 2018
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Xeomin
  • Placebo - Concentrate
Record updated
19 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with focal hand dystonia, a condition causing involuntary cramping or twisting in the hand. It compares IncobotulinumtoxinA (Xeomin) injections with placebo.

Age
18 years and older
Sex
All sexes
Disease stage
Focal hand dystonia diagnosed by a neurologist specialized in movement disorders. Both idiopathic (no known cause) and secondary forms can join.
Earlier treatment
People never treated before and people treated before with other BoNT-A can join. The last BoNT-A treatment must be at least 3 months before joining.

Main reasons for not taking part

  • Spasticity, other brain or spinal lesion of the motor system, or a nerve injury in the affected limb
  • Allergy to BoNT-A toxins, including IncobotulinumtoxinA
  • Pregnancy or breastfeeding
  • Severe depression (>29 on the Beck Depression Inventory) or other relevant psychiatric disorder
  • Another study with an investigational drug in the 30 days before or during this study

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Informed Consent as documented by signature
  • Age ≥ 18 years
  • Focal hand dystonia (FHD). Diagnosis must be made by a neurologist specialized in movement disorder (at least 2 years specific training, all partners listed have at least 2 years training)
  • Both idiopathic and secondary FHD are allowed
  • Both drug naive subjects and subjects previously treated with other BoNT-A will be included
  • Patients must be willing and able to comply with the study procedures
  • Female patients of childbearing potential must agree to use an effective method of contraception during the treatment period

Who cannot take part

  • Doses and schedules of any ongoing treatment with potential confounding drugs such as muscle relaxants (for example Tolperison, Tizinadid, Baclofen, Mestinon, Dantrolen), benzodiazepine, neuroleptics or antidepressants have to be kept unchanged throughout the study and no changes should be made between the first trial injection and the end of study visit at week 12
  • Previous treatment with other BoNT-A less than 3 months before the inclusion in this study
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to BoNT-A toxins including IncobotulinumtoxinA
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Severe depression (>29 as measured with the Beck Depression Inventory, see Appendix 8) or other relevant psychiatric disorder
  • INR > 2 on the day of injection if the patient is anticoagulated. If INR > 2, the study injection will be delayed until the return to a safer INR
  • Presence of spasticity, or other central sensorimotor lesion of motor system other than dystonia in the affected limb
  • Peripheral nerve lesion (diagnosis either clinical or electrophysiological) in the affected limb, for example with a muscle weakness at baseline
  • Women who are pregnant or breast feeding,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Where in Switzerland

  • Inselspital - University Hospital BerneBern, SwitzerlandContact: Niklaus Meier, MDNot yet recruiting
  • Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandContact: David Benninger, MDNot yet recruiting
  • Neurocentro della Svizzera ItalianaLugano, SwitzerlandContact: Alain Kaelin, ProfTaking people
  • Neurocenter of St. GallenSankt Gallen, SwitzerlandContact: Markus Weber, MDNot yet recruiting
  • USZ- Univerity Hospital ZurichZurich, SwitzerlandContact: Hans-Heinr. Jung, Prof.Not yet recruiting

About the trial

What the trial wants to find out

This study is a multicenter, double-blind, randomized placebo controlled, parallel group, superiority trial in order to test the superiority of intramuscular injections of IncobotulinumtoxinA against placebo using a 1:1 allocation ratio.

The 2 groups in the trial

  • Xeomin®Existing treatment, for comparison

    Intramuscular IncobotulinumtoxinA (Xeomin®) injection under guidance (EMG and/or sonographic monitoring), 2.5 to 40 U in each muscle (max. 5 forearm- and/or hand muscles).

  • Placebo concentratePlacebo, for comparison

    Intramuscular Placebo injection under guidance (EMG and/or sonographic monitoring), in each muscle (max. 5 forearm- and/or hand muscles).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia: a Double-blind Placebo-controlled Randomized Multicenter Study: The "SwissHandSpasm" Study
Plain-language title
Xeomin injections compared with placebo for focal hand dystoniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
19 March 2026